No quarterly revenue total was found in ESTRELLA IMMUNOPHARMA, INC.'s SEC filings.
Estrella Immunopharma, Inc. (ESLA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
$-2.31M
+58.4% vs year-ago quarter
Operating cash flow
$-1.78M
-329.2% vs year-ago quarter
Free cash flow
—
EPS
$-0.05
+66.7% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
43.50M
+17.4% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ESLA (Nasdaq), ESLAW (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1844417
- Former names
- TradeUP Acquisition Corp. (until Sep 20, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.1M | -$2.3M | -$613,199 | -$4.8M | -$5.5M |
| Net income | -$2.3M | -$2.3M | -$613,174 | -$4.8M | -$5.5M |
| Diluted EPS | -$0.05 | -$0.05 | -$0.02 | -$0.13 | -$0.15 |
| Operating cash flow | -$1.8M | -$6.7M | -$177,487 | -$727,332 | -$414,879 |
| Total assets | $1.8M | $3.7M | $3.2M | $3.5M | $3.0M |
| Total liabilities | $9.3M | $8.9M | $13.5M | $13.4M | $9.1M |
| Stockholders' equity | -$7.4M | -$5.3M | -$10.4M | -$9.8M | -$6.1M |
| Cash and investments | $100,000 | — | $1.4M | $1.6M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Oct 29, 2026 | Oct 25, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 8, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 21, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 30, 2026 | Jun 29, 2026 |
| 10-Q | Quarterly report | May 18, 2026 | Mar 31, 2026 |
All 258 Estrella Immunopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.